The beat goes on: On the importance of heart rate in chronic heart failure

European Heart Journal

Volumn 33, Issue 9, 2012, Pages 1044-1045

  Swedberg, Karl ^a   Komajda, Michel ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; DIGOXIN; IVABRADINE; PLACEBO;

BRADYCARDIA; CARDIOTOXICITY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART EJECTION FRACTION; HEART FUNCTION; HEART RATE; HOSPITALIZATION; HUMAN; HYPOTENSION; NAUSEA; NOTE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; VISUAL DISORDER;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CHRONIC DISEASE; HEART FAILURE; HUMANS;

EID: 84860624704     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr483     Document Type: Note

References (16)

1. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823-830.
2. Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Bohm M. Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 2011;100:11-19.
3. Katz AM. Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med 1990;322:100-110.
4. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
5. Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-894.
6. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008;101:865-869.
7. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784-794.
8. Castagno D, Petrie MC, Claggett B, Mcmurray J. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 2012;33:1137-1141.
9. The Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
10. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
11. Lindsay SJ, Kearney MT, Prescott RJ, Fox KA, Nolan J. Digoxin and mortality in chronic heart failure. UK Heart Investigation. Lancet 1999;354:1003.
12. Spargias KS, Hall AS, Ball SG. Safety concerns about digoxin after acute myocardial infarction. Lancet 1999;354:391-392.
13. Adams KF Jr, Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA, Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005;46:497-504.
14. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. J Am Med Assoc 2003;289:871-878.
15. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372: 807-816.
16. Volterrani M, Cice G, Caminiti G, Vitale C, D'Isa S, Perrone Filardi P, Acquistapace F, Marazzi G, Fini M, Rosano GM. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol 2011;151:218-224.